E3 ligase Ligand 5, identified by its CAS number 1264754-13-3, is a small molecule that serves as a selective inhibitor of E3 ubiquitin ligases, which are crucial components in the ubiquitin-proteasome system responsible for protein degradation and regulation. This compound is characterized by its ability to modulate protein interactions and influence cellular pathways by targeting specific E3 ligases. The structure of E3 ligase Ligand 5 typically includes functional groups that enhance its binding affinity and specificity towards its target ligases. Its potential applications span various fields, including cancer research, where it may help in the development of therapeutic strategies by manipulating protein turnover and stability. Additionally, due to its role in cellular signaling and homeostasis, E3 ligase Ligand 5 may also be explored for its implications in other diseases linked to protein misfolding or degradation. As with many small molecules, its efficacy and safety profile would be evaluated through preclinical and clinical studies to determine its therapeutic potential.

E3L-4133, also known as E3 ligase Ligand 5, is an E3 ligase Ligand  that can be used in PROTAC (proteolysis targeting chimera) technology to engage an E3 ubiquitin ligase. PROTAC is a two-headed molecule capable of removing specific unwanted proteins.

E3 ligase Ligand 5

1264754-13-3: E3 ligase Ligand 5, identified by its CAS number 1264754-13-3, is a small molecule that serves as a selective inhibitor of E3 ubiquitin ligases, which are crucial components in the ubiquitin-proteasome system responsible for protein degradation and regulation. This compound is characterized by its ability to modulate protein interactions and influence cellular pathways by targeting specific E3 ligases. The structure of E3 ligase Ligand 5 typically includes functional groups that enhance its binding affinity and specificity towards its target ligases. Its potential applications span various fields, including cancer research, where it may help in the development of therapeutic strategies by manipulating protein turnover and stability. Additionally, due to its role in cellular signaling and homeostasis, E3 ligase Ligand 5 may also be explored for its implications in other diseases linked to protein misfolding or degradation. As with many small molecules, its efficacy and safety profile would be evaluated through preclinical and clinical studies to determine its therapeutic potential.

<p>PROTAC ERRα ligand 1 is an α (ERRα) antagonist of estrogen-related receptor (IC50s of 0.04 and 2.8 μM for ERRα and ERRγ, respectively).</p>

CAS 1264754-13-3

E3 ligase Ligand 5

PROTAC ERRα ligand 1

Ref: TM-T15191

PROTAC ERRα ligand 1

Ref: 54-BUP12505